Peptides · Peptide comparison
Pemvidutide vs Survodutide
Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
- Weight Management
- Weight Management
At a glance
Quick comparison
Dose rangePemvidutide1.8–1.8 mgSurvodutide3.6–3.6 mg
FrequencyPemvidutideOnce dailySurvodutideOnce daily
AdministrationPemvidutideSubcutaneous injectionSurvodutidesubcutaneous injection
Cycle lengthPemvidutideOngoing/indefiniteSurvodutideOngoing/indefinite
Onset speedPemvidutideModerate (1-2 weeks)SurvodutideModerate (1-2 weeks)
Evidence levelPemvidutideModerate human trials (Phase 1-2)SurvodutideStrong human trials (Phase 3 or FDA approved)
Efficacy
Benefit ratings
Weight Loss
Liver Health
Metabolic Health
Weight Management
Blood Sugar Control
Technical data
Compound specifications
Pemvidutide
- Molecular formula
- C182H275N39O54
- Molecular weight
- 3873.35 Da
- Half-life
- Approximately 110 hours (4.6 days)
- Bioavailability
- Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
- CAS number
- 2538014-94-5
Survodutide
- Molecular formula
- C192H289N47O61
- Molecular weight
- 4,231.6 Da
- Half-life
- ~7 days (enabling once-weekly dosing)
- Bioavailability
- Optimized for subcutaneous administration with C18 acylation
- CAS number
- 2805997-46-8
Protocols
Dosing compared
Pemvidutide
Subcutaneous
- 48 weeks1.2 mgOnce weekly · 48 weeksLowest dose studied; given at full strength from week 1 with no titration. Produced ~10% weight loss at 48 weeks in the MOMENTUM Phase 2 obesity trial [6] and is the lower MASH dose in the IMPACT Phase 2b trial [7].
- 48 weeks1.8 mgOnce weekly · 48 weeksMid dose, started at full strength with no titration; ~11% weight loss at 48 weeks (MOMENTUM) [6] and the higher MASH dose in IMPACT [7].
- 48 weeks2.4 mgOnce weekly · 48 weeksHighest dose; reached via a 4-week titration in MOMENTUM, where it produced 15.6% weight loss at 48 weeks [6].
Survodutide
Subcutaneous
- Initiation, part of a 20-week up-titration0.6 mgOnce weekly · Initiation, part of a 20-week up-titrationPhase 2 starting dose; gradual escalation reduces GI side effects [1].
- 26-week maintenance after escalation3.6 mgOnce weekly · 26-week maintenance after escalationMaintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss [1].
- 26-week maintenance after escalation4.8 mgOnce weekly · 26-week maintenance after escalationHighest dose studied; up to ~14.9% mean weight loss over 46 weeks [1].
Applications
Best suited for
Pemvidutide
- Adults seeking substantial weight loss without complex dose titration
- Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
- Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].
- Patients with metabolic syndrome who need comprehensive risk factor improvement
- Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Those interested in investigational dual agonist therapies with strong early data
- Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].
Survodutide
- Significant body weight reduction in obesity
- Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- MASH/NASH resolution and liver fibrosis improvement
- Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Type 2 diabetes management with concurrent weight loss goals
- Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Enhanced metabolic outcomes through dual receptor engagement
- Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Pemvidutide
Common
- Nausea
- Diarrhea
- Headache
Uncommon
- Vomiting
- Decreased Appetite
Serious
- Acute Pancreatitis
- Severe Gastrointestinal Disturbance
Survodutide
Common
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
Uncommon
- Constipation and Abdominal Pain
Serious
- Acute Pancreatitis
Research status
Safety & evidence
Pemvidutide
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Pemvidutide (ALT-801, developed by Altimmune; a GLP-1/glucagon dual agonist) [3][5] completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Known hypersensitivity to pemvidutide or formulation components
- History of acute pancreatitis
- Severe hepatic decompensation (Child-Pugh C cirrhosis)
Survodutide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- Research compound
- Safety overview
- Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (gastrointestinal events in 75% on survodutide vs 42% on placebo in the obesity trial [1]; nausea 66%, diarrhea 49% and vomiting 41% in the MASH trial [6]) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Contraindications
- Personal or family history of medullary thyroid carcinoma (GLP-1 class warning)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to survodutide or excipients
- History of pancreatitis (caution advised with GLP-1 receptor agonists)
Decision guide
Which is right for you?
Pemvidutide
Choose Pemvidutide if…
- Adults seeking substantial weight loss without complex dose titration
- Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
- Patients with metabolic syndrome who need comprehensive risk factor improvement
- Those interested in investigational dual agonist therapies with strong early data
Survodutide
Choose Survodutide if…
- Significant body weight reduction in obesity
- MASH/NASH resolution and liver fibrosis improvement
- Type 2 diabetes management with concurrent weight loss goals
- Enhanced metabolic outcomes through dual receptor engagement